Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1969 1
1972 3
1973 3
1974 3
1975 3
1977 1
1978 7
1979 4
1980 7
1981 3
1982 6
1983 10
1984 5
1985 9
1986 14
1987 8
1988 5
1989 11
1990 10
1991 8
1992 6
1993 13
1994 10
1995 12
1996 28
1997 19
1998 21
1999 14
2000 27
2001 27
2002 23
2003 31
2004 34
2005 40
2006 46
2007 62
2008 56
2009 41
2010 51
2011 60
2012 74
2013 89
2014 90
2015 98
2016 103
2017 118
2018 132
2019 131
2020 177
2021 230
2022 200
2023 170
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

2,159 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: perez garcia jm. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: perez garcia j. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
Reply.
Perez-Garcia J, Pino-Yanes M, Lorenzo-Diaz F. Perez-Garcia J, et al. J Allergy Clin Immunol. 2023 Dec;152(6):1683-1685. doi: 10.1016/j.jaci.2023.08.023. Epub 2023 Sep 22. J Allergy Clin Immunol. 2023. PMID: 37747396 No abstract available.
The imprinted Igf2-Igf2r axis is critical for matching placental microvasculature expansion to fetal growth.
Sandovici I, Georgopoulou A, Pérez-García V, Hufnagel A, López-Tello J, Lam BYH, Schiefer SN, Gaudreau C, Santos F, Hoelle K, Yeo GSH, Burling K, Reiterer M, Fowden AL, Burton GJ, Branco CM, Sferruzzi-Perri AN, Constância M. Sandovici I, et al. Among authors: perez garcia v. Dev Cell. 2022 Jan 10;57(1):63-79.e8. doi: 10.1016/j.devcel.2021.12.005. Epub 2021 Dec 27. Dev Cell. 2022. PMID: 34963058 Free PMC article.
Development of an mRNA replacement therapy for phenylketonuria.
Perez-Garcia CG, Diaz-Trelles R, Vega JB, Bao Y, Sablad M, Limphong P, Chikamatsu S, Yu H, Taylor W, Karmali PP, Tachikawa K, Chivukula P. Perez-Garcia CG, et al. Mol Ther Nucleic Acids. 2022 Feb 28;28:87-98. doi: 10.1016/j.omtn.2022.02.020. eCollection 2022 Jun 14. Mol Ther Nucleic Acids. 2022. PMID: 35356682 Free PMC article.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. Among authors: perez garcia jm. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
Superinfected scabies.
Berna-Rico E, Chamorro-Tojeiro S, Pérez-González A, Pérez-García B. Berna-Rico E, et al. Among authors: perez garcia b. Med Clin (Barc). 2024 Feb 9;162(3):145. doi: 10.1016/j.medcli.2023.06.048. Epub 2023 Aug 9. Med Clin (Barc). 2024. PMID: 37567823 English, Spanish. No abstract available.
Engineered tRNAs suppress nonsense mutations in cells and in vivo.
Albers S, Allen EC, Bharti N, Davyt M, Joshi D, Perez-Garcia CG, Santos L, Mukthavaram R, Delgado-Toscano MA, Molina B, Kuakini K, Alayyoubi M, Park KJ, Acharya G, Gonzalez JA, Sagi A, Birket SE, Tearney GJ, Rowe SM, Manfredi C, Hong JS, Tachikawa K, Karmali P, Matsuda D, Sorscher EJ, Chivukula P, Ignatova Z. Albers S, et al. Among authors: perez garcia cg. Nature. 2023 Jun;618(7966):842-848. doi: 10.1038/s41586-023-06133-1. Epub 2023 May 31. Nature. 2023. PMID: 37258671 Free PMC article.
2,159 results